Cure8 research brief
People with ulcerative colitis taking etrasimod may have higher drug levels if they have certain CYP2C9 genotypes or significant liver impairment; dose adjustments could be needed to avoid increased exposure.
The paper provides model-based dosing guidance for affected subgroups, which is directly relevant to clinicians prescribing etrasimod and to patients with liver disease or known CYP2C9 variants.
Clinicians prescribing etrasimod, clinical pharmacologists, researchers in IBD therapeutics, and adults with ulcerative colitis — especially patients with known CYP2C9 variants or hepatic impairment.
This study used a physiologically based pharmacokinetic (PBPK) model to assess how CYP2C9 genetic variants and different levels of hepatic impairment affect exposure to etrasimod, an oral S1P receptor modulator approved for moderate-to-severe ulcerative colitis.
The model was verified against clinical and in vitro data and then applied to Chinese populations to predict steady‑state concentrations and AUC.
The model predicted that both CYP2C9 poor metabolizer status and worsening hepatic impairment increase etrasimod exposure, with the largest effect when both are present (e.g., predicted ~67% higher AUC in poor metabolizers with Child–Pugh C).
Based on exposure-matching, the authors propose dose reductions from the approved 2 mg daily to 1.5 mg for most affected subgroups and to 1 mg daily for poor metabolizers with severe hepatic impairment. This article presents a model-based pharmacokinetic analysis and dose‑optimization recommendations rather than new clinical outcome data.
It helps quantify how genotype and liver function could change drug levels and supports individualized dosing considerations.
Structured content depth: abstract — this brief is grounded in the journal abstract and model results provided in the article. The work is a PBPK modelling study and provides predicted exposure and suggested dose adjustments; it does not present prospective clinical outcome data validating those dose changes.
Genetic testing (CYP2C9) and formal liver function assessment are the contexts in which these recommendations would be applied.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Individual factors like CYP2C9 genotype and liver impairment can raise etrasimod levels. The study’s model-based dose suggestions could help personalize dosing to reduce risk of excess exposure.
This abstract reports that etrasimod improved multiple measures of disease activity versus placebo in patients who had inadequate response to conventional UC therapies, indicating it may be a useful first-line advanced...
S1P receptor modulators are an emerging oral class of advanced therapy for moderate-to-severe ulcerative colitis; a systematic review that pools multiple RCTs helps clarify how effective and safe the class appears to be...
